Partnership / Collaboration · GCC · Announced 29 Aug 2026
AstraZeneca → KAIMRC
Partnership / Collaboration deal between AstraZeneca (United Kingdom) and KAIMRC (Saudi Arabia), announced 29 Aug 2026.
Parties: AstraZeneca (United Kingdom) → KAIMRC (Saudi Arabia)
- Deal type
- Partnership / Collaboration
- Value
- Not stated
- Territory
- Saudi Arabia
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Pre-clinical — building pre-clinical models; identifying/optimizing therapeutic candidates
- Announced
- 29 Aug 2026
Our analysis
A joint pre-clinical research program to develop CRISPR therapeutic candidates for ASL deficiency, paired with KAIMRC workforce development. The named participants place it precisely: Dr. Marcello Maresca, AstraZeneca's Senior Director of Genome Engineering (on the summit's "Saudi Gene Therapy Localization Journey" panel) and Dr. Seng H. Cheng, SVP & Head of R&D at Alexion, AstraZeneca Rare Disease.
So this isn't generic pharma R&D — it runs through AstraZeneca's CRISPR/genome-engineering group and its dedicated rare-disease genomic-medicine engine (Alexion) , the two units actually equipped to attempt an editing therapy.
The full analysis is free to read with a work email on this page.